The clinical usefulness of an immunotest was evaluated by using purified poly(adenosine diphosphate (ADP)-ribose) polymerase from Sulfolobus solfataricus (PARPSso) as an antigen to detect the presence of abnormal anti-PARP antibodies in the sera of patients with systemic lupus erythematosus (SLE) at different clinical stages. Sera from 44 patients with SLE, subgrouped on the basis of disease activity (16 with inactive disease, 28 with active disease) were analysed with a new immunotest to detect anti-PARP antibodies, and with an immunofluorescent (IIF) assay for antinuclear antibodies (ANA) detection. ANA detection by IIF revealed that sera of healthy subjects were negative, whereas sera from patients with SLE were positive in all cases (13 positive at 1:80, 15 at 1:160, 15 at 1:320, 1 at 1:640, v/v). Anti-PARP activity was higher in ANA-positive patients than in controls (p = 0.005). Within the group of SLE sera, disease and anti-PARP activity was increased more significantly in patients with active than in those with inactive disease (p < 0.001 and p = 0.001, respectively). Correlation between anti-PARP and disease activity in SLE patients was statistically significant (p < 0.001). PARPSso seems to be suitable for detecting anti-PARP antibodies and could play a role as a serological marker of disease activity in patients with SLE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13547500902987033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
Diagnostics (Basel)
January 2021
Institute of Obstetrics and Gynecology, University of Debrecen, 4032 Debrecen, Egyetem tér 1., Hungary.
(1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance. (2) Methods: Immunostaining to highlight PARP protein expression was performed using a rabbit polyclonal anti-PARP antibody.
View Article and Find Full Text PDF[Innovations in systemic treatment of urothelial carcinoma].
Bull Cancer
June 2020
Service d'oncologie médicale, Hôpital Saint-André, CHU de Bordeaux, 1, rue Jean-Burguet, 33075 Bordeaux, France. Electronic address:
Until 2014, no new therapeutic agent have been approved by authorities in more than 2 decades for bladder cancer. But the panel of treatments has expended in recent years with the emergence of at least 3 different therapeutic classes. First, the immune checkpoint inhibitors that have demonstrated an overall survival benefit in metastatic patients after failure of platinum based chemotherapy.
View Article and Find Full Text PDFThe Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Pathol Oncol Res
October 2020
Institute of Obstetrics and Gynaecology, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
In an attempt to clarify the prognostic relevance of poly (ADP-ribose) polymerase (PARP) expression, we analysed the clinical data of 86 high-grade epithelial ovarian cancer (EOC) cases in which PARP immunohistochemistry results were available. Immunostaining to highlight PARP protein expression was performed using a Leica Bond MAX Immunostainer (Leica Microsystems, Wetzlar, Germany). We applied a rabbit polyclonal anti-PARP antibody (ab6079 330, Abcam, Cambridge, UK) for the specific reaction.
View Article and Find Full Text PDF[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?].
Bull Cancer
October 2018
Laboratoire de biologie cellulaire, hôpital Arnaud-de-Villeneuve, unité d'oncologie thoracique, avenue du Doyen-Giraud, 34295 Montpellier cedex, France.
Small cell lung cancer accounts for 14% of all lung cancers. It remains a major challenge for oncology as the progresses made in the past three decades are modest. After a rapid overview of current knowledge regarding somatic genomic alterations, this state-of-art addresses pathways to improve small-cell lung cancer outcome such as the targeting of DNA damage repair mechanisms firstly anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, temozolomide and its dependence on methylation of the MGMT promoter.
View Article and Find Full Text PDFPARP-1 expression in CD34+ leukemic cells in childhood acute lymphoblastic leukemia: relation to response to initial therapy and other prognostic factors.
Pol J Pathol
September 2015
Elżbieta Urasińska MD, PhD, Department of Pathology, Pomeranian Medical University, Unii Lubelskiej St. 1, 71-252 Szczecin, Poland, tel. +48 91 487 00 32, e-mail:
Article Synopsis
- PARP-1 is a nuclear protein involved in DNA repair and apoptosis, making it a target for anticancer therapies, especially in leukemia.
- A study on 43 children with acute lymphoblastic leukemia (ALL) examined PARP-1 expression in their blood cells before and after prednisone treatment, looking for connections to treatment response and other factors.
- The results indicated that while PARP-1 levels did not vary significantly with different prognostic indicators, they increased in poor early responders after treatment, suggesting a potential role in treatment failure and the possibility of using PARP inhibitors in certain ALL patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!